


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:48:51Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405119" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405119</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>discon</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Discov Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Discov Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">4139</journal-id><journal-id journal-id-type="pmc-domain">discon</journal-id><journal-title-group><journal-title>Discover Oncology</journal-title></journal-title-group><issn pub-type="epub">2730-6011</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405119</article-id><article-id pub-id-type="pmcid-ver">PMC12405119.1</article-id><article-id pub-id-type="pmcaid">12405119</article-id><article-id pub-id-type="pmcaiid">12405119</article-id><article-id pub-id-type="pmid">40892354</article-id><article-id pub-id-type="doi">10.1007/s12672-025-03509-9</article-id><article-id pub-id-type="publisher-id">3509</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title><italic toggle="yes">SLC38A4</italic> as a prognostic biomarker and correlated with immune infiltration in colorectal liver metastasis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Ying</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wei</surname><given-names initials="X">Xin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="N">Ningning</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5576-7979</contrib-id><name name-style="western"><surname>Wang</surname><given-names initials="W">Weijia</given-names></name><address><email>wwjsxsrmyy@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/009czp143</institution-id><institution-id institution-id-type="GRID">grid.440288.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1758 0451</institution-id><institution>Department of Medical Oncology, </institution><institution>Shaanxi Provincial People&#8217;s Hospital, </institution></institution-wrap>No. 256 Youyi West Road, Xi&#8217;an, 710068 People&#8217;s Republic of China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/017zhmm22</institution-id><institution-id institution-id-type="GRID">grid.43169.39</institution-id><institution-id institution-id-type="ISNI">0000 0001 0599 1243</institution-id><institution>Department of Medical Oncology, First Affiliated Hospital, </institution><institution>Xi&#8217;an Jiaotong University, </institution></institution-wrap>Xi&#8217;an, China </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">478248</issue-id><elocation-id>1675</elocation-id><history><date date-type="received"><day>21</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>26</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12672_2025_Article_3509.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Colorectal liver metastasis (CRLM) is the most frequent form of metastasis and the main reason for deaths associated with colorectal cancer. However, prognostic biomarkers originating from CRLM tissue remain limited. Additionally, the impact of the metabolism-associated gene SLC38A4 on patients with CRLM remains elusive.</p></sec><sec><title>Methods</title><p id="Par2">Metabolism-related differentially expressed genes (MRDEGs) were identified between CRLM and adjacent normal liver (NL) tissues using GEO datasets (<ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE38174">GSE38174</ext-link>, <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE41258">GSE41258</ext-link>). The prognostic significance of these MRDEGs in CRLM (<ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE159216">GSE159216</ext-link>) was evaluated using Cox regression and Kaplan-Meier survival analyses. The differential expression of SLC38A4 was validated through multiple experiments, including qRT-PCR, Western blotting, and immunohistochemistry. Genes co-expressed with SLC38A4 were identified through a weighted gene co-expression network analysis, and enrichment analyses were conducted by <italic toggle="yes">clusterProfiler</italic>. The link between SLC38A4 and immune infiltration was assessed with the <italic toggle="yes">CIBERSORT</italic> algorithm, while drug sensitivity was analyzed using <italic toggle="yes">oncoPredict</italic>.</p></sec><sec><title>Results</title><p id="Par3">SLC38A4 was identified as an independent favorable-prognosis biomarker for CRLM, with significantly lower expression in CRLM compared to NL tissues. Enrichment analyses indicated that SLC38A4-associated genes participate in diverse metabolic processes. Immune infiltration analysis indicated that SLC38A4 expression is linked to the infiltration of immune cells and three immune checkpoint genes: ARG1, EDNRB, and TNFSF4. Additionally, multiple anti-tumor drugs were positively associated with SLC38A4 expression.</p></sec><sec><title>Conclusion</title><p id="Par4">Elevated SLC38A4 expression is correlated with a favorable prognosis in CRLM, likely through mechanisms involving metabolic reprogramming and immune infiltration. Thus, SLC38A4 may serve as both a prognostic biomarker and a potential biomarker for future therapeutic investigation, offering new precision medicine options for CRLM patients.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s12672-025-03509-9.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>SLC38A4</kwd><kwd>Prognostic biomarker</kwd><kwd>Colorectal liver metastasis</kwd><kwd>Immune infiltration</kwd><kwd>Metabolic reprogramming.</kwd></kwd-group><funding-group><award-group><funding-source><institution>Beijing Xisike Clinical Oncology Research Foundation</institution></funding-source><award-id>Y-HH202101-0234</award-id><principal-award-recipient><name name-style="western"><surname>Wei</surname><given-names>Xin</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par23">Colorectal cancer (CRC) ranks as the second highest cause of cancer-related mortality globally, contributing to 9.3% of all deaths [<xref ref-type="bibr" rid="CR1">1</xref>]. Colorectal liver metastasis (CRLM)&#8212;the most prevalent type of CRC metastasis&#8212;is the chief cause of CRC-related mortality [<xref ref-type="bibr" rid="CR2">2</xref>]. With the progression of CRC, approximately 25&#8211;50% of diagnosed individuals will develop CRLM, either metachronous or synchronous [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Radical resection combined with chemotherapy is still the typical therapy for CRLM [<xref ref-type="bibr" rid="CR5">5</xref>]. However, surgical intervention is possible for only 10&#8211;20% of cases, with a 35% survival rate after five years [<xref ref-type="bibr" rid="CR6">6</xref>]. The remaining patients ineligible for surgery show a poor prognosis [<xref ref-type="bibr" rid="CR7">7</xref>]. Therefore, targeting liver metastasis is crucial for enhancing the therapeutic outcomes of patients with CRC by identifying potential biomarkers and novel therapeutic targets.</p><p id="Par24">Biomarkers are central to cancer management, including differential diagnosis, prediction, and assessment of treatment response in CRC [<xref ref-type="bibr" rid="CR8">8</xref>]. However, limited studies have identified prognostic biomarkers for CRLM. Previous studies have demonstrated that mutations in genes, including <italic toggle="yes">RAS</italic>, <italic toggle="yes">BRAF</italic>, <italic toggle="yes">TP53</italic>, and <italic toggle="yes">SMAD4</italic>, as well as protein biomarkers like THBS1, are predictors of poor prognosis in CRLM [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Bioinformatics has facilitated the identification of potential tumor biomarkers, primarily through gene differential expression analysis, hub gene screening, and regulatory network construction, such as miRNA-mRNA networks [<xref ref-type="bibr" rid="CR11">11</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref>]. Additionally, some studies have identified prognostic biomarkers for CRLM, such as <italic toggle="yes">GAS1</italic>, <italic toggle="yes">IMPA2</italic>, <italic toggle="yes">C5</italic>, <italic toggle="yes">CDH2</italic>, and <italic toggle="yes">SPARCL1</italic> [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR15">15</xref>&#8211;<xref ref-type="bibr" rid="CR17">17</xref>]. However, most of these biomarkers are derived from CRC tissues, which do not accurately reflect the heterogeneity of CRLM [<xref ref-type="bibr" rid="CR18">18</xref>]. HER2 amplification in liver metastasis tissues is linked to a worse prognosis in individuals with wild-type RAS/RAF genes and left-sided CRLM [<xref ref-type="bibr" rid="CR19">19</xref>]. Decreased CDX2 expression and elevated CD73 expression in liver metastatic lesions predict a poor prognosis [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. However, these prognostic biomarkers derived specifically from CRLM tissues remain scarce. This necessitates finding optimal biomarkers specific to CRLM tissues to enhance the efficacy of targeted therapies.</p><p id="Par25">Solute carrier family 38 member 4 (<italic toggle="yes">SLC38A4</italic>)&#8212;also known as sodium-coupled neutral amino acid transporter 4&#8212;belongs to the amino acid transporter system A. This Na+-dependent transporter mediates the uptake of neutral amino acids [<xref ref-type="bibr" rid="CR22">22</xref>], which are essential for the proliferation of rapidly dividing cells, particularly cancer cells [<xref ref-type="bibr" rid="CR23">23</xref>]. However, studies on <italic toggle="yes">SLC38A4</italic> in cancer are sparse. <italic toggle="yes">SLC38A4</italic> can inhibit hepatocellular carcinoma (HCC) progression [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Nevertheless, its role in other cancers, particularly liver metastatic cancers, including CRLM, remains unclear. Therefore, the investigation focused on determining the prognostic significance of <italic toggle="yes">SLC38A4</italic> in CRLM and its impact on metabolic and immune functions.</p><p id="Par26">In the research, we explored the metabolism-related differentially expressed genes (MRDEGs) in CRLM tissues compared to nearby normal liver (NL) tissues. <italic toggle="yes">SLC38A4</italic> was found to be a favorable prognostic biomarker and a tumor suppressor gene in CRLM. Furthermore, the weighted gene co-expression network analysis (WGCNA) method was applied to find <italic toggle="yes">SLC38A4</italic>-associated genes, followed by functional enrichment analyses. Finally, immune cell infiltration and drug sensitivity investigations demonstrated the role of <italic toggle="yes">SLC38A4</italic> in CRLM. Taken together, <italic toggle="yes">SLC38A4</italic> might be a novel prognostic biomarker and a potential candidate for future therapeutic investigation.</p></sec><sec id="Sec2"><title>Method</title><sec id="Sec3"><title>Public database</title><p id="Par27">The Gene Expression Omnibus (GEO) database provided three datasets: <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE38174">GSE38174</ext-link>, <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE41258">GSE41258</ext-link>, and <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE159216">GSE159216</ext-link>. <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE38174">GSE38174</ext-link> and <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE41258">GSE41258</ext-link> included gene expression profiles of 30 and 9 paired CRLM and NL tissues, respectively, which were used to identify MRDEGs. <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE159216">GSE159216</ext-link> encompassed gene expression profiles and clinical information on CRLM tissues. To ensure reliable analysis, samples lacking complete survival data were excluded, and this dataset was designated as the CRLM cohort.</p></sec><sec id="Sec4"><title>Identifying MRDEGs</title><p id="Par28">In <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE38174">GSE38174</ext-link> and <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE41258">GSE41258</ext-link>, the <italic toggle="yes">Limma</italic> package identified differentially expressed genes (DEGs) with thresholds of |log2FC| &gt; 2 and adjusted <italic toggle="yes">p</italic>-values&#8201;&lt;&#8201;0.05. The results were then visualized through Volcano plots. Metabolism-related genes (MRGs), which encode human metabolic enzymes and transporters, were sourced from previous studies [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. The intersection of DEGs and MRGs yielded MRDEGs, which were analyzed in the CRLM cohort.</p></sec><sec id="Sec5"><title>Prognostic and survival analyses</title><p id="Par29">In the CRLM cohort, the expression values of MRDEGs were integrated with clinicopathological variables, including sex, type of liver metastasis, liver resection margin status, extrahepatic metastasis, <italic toggle="yes">KRAS</italic>, <italic toggle="yes">NRAS</italic>, and <italic toggle="yes">TP53</italic> mutation status. The prognostic impact of these MRDEGs was then determined through Cox regression analysis. Subsequently, the Kaplan-Meier approach, along with a log-rank test, was employed to further evaluate their effects on survival outcomes. The <italic toggle="yes">survival</italic> and <italic toggle="yes">survminer</italic> R packages were used, with statistical significance indicated by a <italic toggle="yes">p</italic>-value below 0.05.</p></sec><sec id="Sec6"><title>Differential expression analysis of SLC38A4</title><p id="Par30">The transcriptional expression of <italic toggle="yes">SLC38A4</italic> in paired CRLM and NL tissues was analyzed using datasets <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE38174">GSE38174</ext-link> and <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE41258">GSE41258</ext-link>, along with real-time quantitative reverse transcription PCR (qRT-PCR). Meanwhile, the translational expression of <italic toggle="yes">SLC38A4</italic> was validated through Western blotting and immunohistochemistry (IHC) using in-house tissue samples.</p></sec><sec id="Sec7"><title>SLC38A4-related modules and genes screened by WGCNA</title><p id="Par31">Co-expression modules related to <italic toggle="yes">SLC38A4</italic> were identified through WGCNA. These modules were then examined for their correlation with CRLM phenotype. The most significant module was selected for further analysis. Hub genes were identified based on their high gene significance and module membership, with both metrics exceeding 0.5.</p></sec><sec id="Sec8"><title>Functional enrichment analyses</title><p id="Par32">Through the <italic toggle="yes">clusterProfiler</italic> package, Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were carried out on co-expressed genes associated with <italic toggle="yes">SLC38A4</italic> [<xref ref-type="bibr" rid="CR28">28</xref>]. Significance was determined by adjusted <italic toggle="yes">p</italic>-values&#8201;&lt;&#8201;0.05.</p><p id="Par33">Based on the median level of <italic toggle="yes">SLC38A4</italic>, individuals with CRLM were grouped into low- and high-expression categories. Gene set enrichment analysis (GSEA) was then conducted through the <italic toggle="yes">clusterProfiler</italic> [<xref ref-type="bibr" rid="CR28">28</xref>], with statistical significance considered for a false discovery rate below 0.05.</p></sec><sec id="Sec9"><title>Immune infiltration analysis</title><p id="Par34">Utilizing the <italic toggle="yes">CIBERSORT</italic> algorithm [<xref ref-type="bibr" rid="CR29">29</xref>], the tumor microenvironment (TME) of CRLM was analyzed. It estimated the infiltration levels for 22 distinct types of immune cells. To explore the connection between <italic toggle="yes">SLC38A4</italic> expression and the infiltrates of immune cells, Pearson correlation analyses were then conducted.</p><p id="Par35">Additionally, 60 immune checkpoint genes, with 24 functioning as immune inhibitors and 36 as immune stimulators, were selected from previous research [<xref ref-type="bibr" rid="CR30">30</xref>]. Pearson correlation analyses assessed the associations between the mentioned genes and <italic toggle="yes">SLC38A4</italic> expression. <italic toggle="yes">P</italic> values less than 0.05 indicated significance, with correlations categorized as moderate or strong (<italic toggle="yes">R</italic>&#8201;&gt;&#8201;0.30) and weak (<italic toggle="yes">R</italic>&#8201;&lt;&#8201;0.30).</p></sec><sec id="Sec10"><title>Drug sensitivity analysis</title><p id="Par36">The Genomics of Drug Sensitivity in Cancer database supplied the drug information data [<xref ref-type="bibr" rid="CR31">31</xref>]. The IC50 values for various drugs were assessed according to <italic toggle="yes">SLC38A4</italic> expression using the <italic toggle="yes">oncoPredict</italic> package [<xref ref-type="bibr" rid="CR32">32</xref>]. Additionally, Pearson&#8217;s tests were utilized to calculate correlation coefficients, with <italic toggle="yes">P</italic> values below 0.05 indicating significance.</p></sec><sec id="Sec11"><title>Sample collection</title><p id="Par37">Fresh CRLM and matched NL tissues were collected from eight patients during liver metastasis surgical excision and preserved at -80&#160;&#176;C for later analysis. Additionally, twelve paired CRLM and NL formalin-fixed paraffin-embedded (FFPE) pathological sections were acquired. In line with the Declaration of Helsinki, this study received approval from the Ethics Committee of Shaanxi Provincial People&#8217;s Hospital (Approval No. 2023-R156). Each participant gave written informed consent.</p></sec><sec id="Sec12"><title>qRT-PCR</title><p id="Par38">Trizol reagent (Invitrogen, USA) was used to extract total RNA from fresh tissue, followed by the synthesis of cDNA from the RNA extracts using a reverse transcription system (Takara, Japan). Gene expression was quantified through qRT-PCR (Takara, Japan), using GAPDH as an internal reference and the 2^-&#916;&#916;Ct method for result calculation. The specific primer sequences used were as follows: SLC38A4, forward: 5&#8242;-AGGCAGCAATGAGCAGTCAA-3&#8242;, reverse: 5&#8242;-GGTTCCGGGATGGTGTTCAT-3&#8242;; GAPDH, forward: 5&#8242;-TCGGAGTCAACGGATTTGGT-3&#8242;, reverse: 5&#8242;-TTCCCGTTCTCAGCCTTGAC-3&#8242;.</p></sec><sec id="Sec13"><title>Western blotting</title><p id="Par39">Proteins were extracted from fresh tissues using ice-cold RIPA lysis buffer (Cat# P0013; Beyotime, China). After centrifuging the lysates at 13,000 &#215;g for 20&#160;min at 4&#160;&#176;C, the supernatant was collected. Subsequently, a BCA Kit (Cat# 23225; Thermo Fisher Scientific, USA) was used to measure the protein concentration. In the Western blotting experiment, 30&#160;&#181;g of protein per lane was denatured at 95&#160;&#176;C for 5&#160;min, followed by separation using SDS-PAGE and transfer to a PVDF membrane. After blocking with 5% non-fat milk in TBST for 2&#160;h at room temperature, the membrane was incubated overnight at 4&#160;&#176;C with the anti-SLC38A4 primary antibody (1:600; Cat# 20857-1-AP; Proteintech, China). After three 10-minute washes with TBST, the membrane was incubated with an HRP-conjugated anti-rabbit IgG secondary antibody (1:10,000; Cat# ab6721; Abcam, UK) for 2&#160;h at room temperature. Protein bands were visualized using ECL reagent (Cat# 34580; Thermo Fisher Scientific). The membrane was then stripped with Restore Western Blot Stripping Buffer (Cat# 21059; Thermo Fisher Scientific) for 15&#160;min at room temperature, washed extensively with TBST, reblocked, and reprobed with anti-GAPDH (1:3000; Cat# ab263962; Abcam) under identical conditions. Band intensities were quantified using ImageJ software and normalized to GAPDH.</p></sec><sec id="Sec14"><title>Immunohistochemistry</title><p id="Par40">The pathological sections underwent deparaffinization in xylene, followed by rehydration through ethanol solutions of reducing concentrations. Using EDTA buffer at pH 9.0, antigen retrieval was carried out with microwave heating at 95&#160;&#176;C for 20&#160;min. Endogenous peroxidase activity was inhibited using 3% hydrogen peroxide for 10&#160;min, followed by blocking nonspecific antigens with 10% goat serum (Cat# G9023, Sigma, USA) for 1&#160;h. Subsequently, the sections were treated with an anti-SLC38A4 antibody (1:50, Cat# 20857-1-AP, Proteintech, China) for 2&#160;h at 37&#160;&#176;C. Afterward, a biotin-labeled secondary antibody was applied, and DAB chromogenic development was performed for 5&#160;min. After counterstaining with hematoxylin, the sections were dehydrated through graded alcohols and cleared with xylene, after which the slides were mounted with neutral resin. Images were captured using a light microscope (Leica Microsystems, Germany). The staining intensity was quantitatively analyzed using the IHC Profiler plugin in ImageJ [<xref ref-type="bibr" rid="CR33">33</xref>], with results categorized into four levels: high positive, positive, low positive, and negative.</p></sec><sec id="Sec15"><title>Statistical analysis</title><p id="Par41">The differential expression of SLC38A4 was evaluated at the mRNA level using paired t-tests, while protein levels were assessed through unpaired t-tests for Western blotting and chi-square tests for IHC. Pearson&#8217;s test was used to conduct correlational analyses. In determining statistical significance, all analyses used a threshold of <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05.</p></sec></sec><sec id="Sec16"><title>Results</title><sec id="Sec17"><title>Study design</title><p id="Par42">Figure&#160;<xref rid="Fig1" ref-type="fig">1</xref> illustrates the research process. Initially, the MRDEGs between CRLM and NL tissues were determined by overlapping the DEGs and MRGs. <italic toggle="yes">SLC38A4</italic> was identified as a favorable prognostic biomarker for individuals with CRLM. Furthermore, the differential expression of <italic toggle="yes">SLC38A4</italic> and its potential biological function in CRLM were explored. Lastly, the links between <italic toggle="yes">SLC38A4</italic> expression and immune cell infiltration, as well as drug sensitivity, were investigated.</p><p id="Par43">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>The flow diagram showing the process of this study</p></caption><graphic id="d33e634" position="float" orientation="portrait" xlink:href="12672_2025_3509_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec18"><title>Screening MRDEGs between CRLM and NL tissues</title><p id="Par44">Figure&#160;<xref rid="Fig2" ref-type="fig">2</xref> presents a comparative analysis of CRLM and paired NL tissues. The dataset <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE38174">GSE38174</ext-link> included 1,313 DEGs, with 617 genes upregulated and 696 downregulated (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A). Similarly, the <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE41258">GSE41258</ext-link> dataset contained 374 upregulated and 327 downregulated genes (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B). For downstream analysis, 2,752 MRGs&#8212;encoding human transport proteins and metabolic enzymes&#8212;were retrieved from previous studies. The intersection of DEGs and MRGs generated 169 candidate MRDEGs, including 43 upregulated and 126 downregulated MRDEGs (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>C, D), which were selected for further analysis.</p><p id="Par45">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Screening of MRDEGs between CRLM and NL. <bold>A</bold>,<bold> B</bold> Volcano plots for DEGs in <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE38174">GSE38174</ext-link> and <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE41258">GSE41258</ext-link>; <bold>C</bold>,<bold> D</bold> Upregulated and downregulated MRDEGs generated by the intersection of DEGs and MRGs</p></caption><graphic id="d33e673" position="float" orientation="portrait" xlink:href="12672_2025_3509_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec19"><title>SLC38A4 is a favorable prognostic biomarker</title><p id="Par46">The prognostic implications of the 169 MRDEGs in the CRLM cohort were evaluated through univariate Cox regression analyses, which identified 48 MRDEGs significantly related to overall survival (OS) (Supplementary Table 1). Further multivariate Cox regression analyses revealed nine independent prognostic MRDEGs, including <italic toggle="yes">SLC38A4</italic>, <italic toggle="yes">RBKS</italic>, <italic toggle="yes">ASPA</italic>, <italic toggle="yes">CTH</italic>, <italic toggle="yes">ENPP1</italic>, <italic toggle="yes">TF</italic>, <italic toggle="yes">CYP39A1</italic>, <italic toggle="yes">G6PC</italic>, and <italic toggle="yes">FOM3</italic> (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>A). Subsequently, Kaplan-Meier survival analysis stratified patients into low and high expression groups. Notably, only high expression levels of <italic toggle="yes">SLC38A4</italic> (hazard ratio (HR)&#8201;=&#8201;0.489, <italic toggle="yes">p</italic>&#8201;=&#8201;0.00025) and <italic toggle="yes">G6PC</italic> (HR&#8201;=&#8201;0.681, <italic toggle="yes">p</italic>&#8201;=&#8201;0.04638) showed significant connections to OS (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>B). Compared to <italic toggle="yes">G6PC</italic>, <italic toggle="yes">SLC38A4</italic> may demonstrate a stronger survival benefit, as evidenced by its lower HR. Additionally, <italic toggle="yes">SLC38A4</italic> exhibited higher diagnostic accuracy (Area Under Curve (AUC): 0.953 vs. 0.939) and superior 5-year prognostic prediction performance (AUC: 0.635 vs. 0.584) (Fig. S1). Given its predominant expression in hepatic tissue [<xref ref-type="bibr" rid="CR34">34</xref>], dysregulation of <italic toggle="yes">SLC38A4</italic> may directly influence the progression of liver metastasis. Based on its relative robust prognostic power, survival prediction performance, diagnostic discrimination, and liver-specific biological relevance, <italic toggle="yes">SLC38A4</italic> was prioritized for further investigation.</p><p id="Par47">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Prognostic implication of MRDEGs in the CRLM cohort. <bold>A</bold> OS-related prognostic MRDEGs identified by multivariate Cox regression analysis; <bold>B</bold> Kaplan-Meier OS curves for prognostic MRDEGs</p></caption><graphic id="d33e760" position="float" orientation="portrait" xlink:href="12672_2025_3509_Fig3_HTML.jpg"/></fig>
</p></sec><sec id="Sec20"><title>Differential expression of SLC38A4 validated by qRT-PCR, WB, and IHC</title><p id="Par48">At the mRNA expression level, analysis of GEO datasets (<ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE38174">GSE38174</ext-link> and <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE41258">GSE41258</ext-link>) indicated a significant decrease in SLC38A4 expression in CRLM tissues compared to NL tissues (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>A, B). This finding was further validated in our clinical cohort through qRT-PCR analysis of matched CRLM and NL pairs (<italic toggle="yes">n</italic>&#8201;=&#8201;8), which demonstrated a decrease in SLC38A4 expression in CRLM (<italic toggle="yes">p</italic>&#8201;=&#8201;0.01; Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>C). At the protein level, WB analysis detected a specific SLC38A4 band at the expected molecular weight (~&#8201;61&#160;kDa; Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>D). Quantitative analysis revealed significantly lower SLC38A4 protein expression in CRLM samples compared to NL tissues (<italic toggle="yes">p</italic>&#8201;=&#8201;0.0098; Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>E). IHC examination displayed distinct staining patterns (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>F). Generally, the IHC staining patterns of SLC38A4 within the tumor were homogeneous. The majority of SLC38A4-positive cells exhibited membranous and uneven cytoplasmic staining, while nuclear staining was rarely observed. These findings align with the subcellular localization information provided by the GeneCards knowledgebase (<ext-link ext-link-type="uri" xlink:href="https://www.genecards.org/">https://www.genecards.org/</ext-link>) (Fig. S2). Notably, SLC38A4 expression was consistently positive in NL tissues; however, it was downregulated, showing low-positive or negative staining in 91.7% (11 out of 12) of CRLM tissues (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>G, Supplementary Table 2). Statistical analysis confirmed a significantly reduced SLC38A4 staining intensity in CRLM compared to NL tissues (<italic toggle="yes">p</italic>&#8201;=&#8201;0.0083; Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>G), corroborating both the transcriptomic and WB results.</p><p id="Par49">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Validation of SLC38A4 differential expression between CRLM and NL.<bold> A</bold>,<bold> B</bold> SLC38A4 mRNA expression in public GEO datasets;<bold> C</bold> qRT-PCR validation in clinical samples (<italic toggle="yes">n</italic>&#8201;=&#8201;8) confirms reduced SLC38A4 expression in CRLM;<bold> D</bold> Representative western blot of SLC38A4 (~&#8201;61&#160;kDa) in matched CRLM and NL pairs;<bold> E</bold> Quantification of western blot signals;<bold> F</bold> Representative IHC staining of SLC38A4 in matched CRLM and NL tissues;<bold> G</bold> Semi-quantitative analysis of IHC staining intensity</p></caption><graphic id="d33e839" position="float" orientation="portrait" xlink:href="12672_2025_3509_Fig4_HTML.jpg"/></fig>
</p></sec><sec id="Sec21"><title>Potential function of SLC38A4 in CRLM</title><p id="Par50">WGCNA analysis was conducted to identify <italic toggle="yes">SLC38A4</italic>-related genes and investigate its potential counteractive effects in CRLM progression (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>A&#8211;F). Using average linkage hierarchical clustering, 10 modules were identified from the CRLM cohort. Of these, the yellow module contained 530 genes and demonstrated the strongest association with <italic toggle="yes">SLC38A4</italic> expression (correlation coefficient&#8201;=&#8201;0.98, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001) (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>G&#8211;H).</p><p id="Par51">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Identification of SLC38A4-associated modules and genes in CRLM. <bold>A</bold>,<bold> B</bold> Assessment of the scale-free fit index and mean connectivity across different soft-thresholding powers (&#946;); <bold>C</bold>&#8211;<bold>F</bold> Cluster dendrogram of patients with CRLM, with 10 modules clustered; <bold>G</bold> Correlation heatmap between CRLM phenotype and modules; <bold>H</bold> Scatter plot of the yellow module</p></caption><graphic id="d33e888" position="float" orientation="portrait" xlink:href="12672_2025_3509_Fig5_HTML.jpg"/></fig>
</p><p id="Par52">The analysis of GO term annotation for these 530 genes suggested that <italic toggle="yes">SLC38A4</italic> is significantly linked to biological processes, primarily metabolic and catabolic processes (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>A). Cellular component analysis identified its presence in the collagen-containing extracellular matrix, blood microparticle, and vesicle lumen. Molecular function analysis demonstrated the role of <italic toggle="yes">SLC38A4</italic> in enzymatic activities, such as peptidase, endopeptidase, monooxygenase, and oxidoreductase activities. KEGG pathway analysis elucidated the involvement of <italic toggle="yes">SLC38A4</italic> in drug metabolism, xenobiotic metabolism by cytochrome P450, retinol metabolism, and fatty acid degradation (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>B).</p><p id="Par53">Additionally, GSEA results suggested that high <italic toggle="yes">SLC38A4</italic> expression is predominantly linked to metabolic pathways, such as glycerolipid, glutathione, pyruvate, galactose, fructose, and mannose metabolism (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>C). Thus, <italic toggle="yes">SLC38A4</italic> may play an important role in regulating metabolic reprogramming during CRLM.</p><p id="Par54">
<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Potential functions of SLC38A4 in CLRM. <bold>A</bold>,<bold> B</bold> Examination of SLC38A4 and its related genes through GO and KEGG; <bold>C</bold> Enriched pathway analysis of the high-expression SLC38A4 group by GSEA</p></caption><graphic id="d33e936" position="float" orientation="portrait" xlink:href="12672_2025_3509_Fig6_HTML.jpg"/></fig>
</p></sec><sec id="Sec22"><title>Immune infiltration analysis of SLC38A4</title><p id="Par55">Given the capacity of cancer cells to promote tumor growth by inhibiting immune responses in the progression of CRLM [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>], the role of <italic toggle="yes">SLC38A4</italic> in tumor immunity was investigated. Figure&#160;<xref rid="Fig7" ref-type="fig">7</xref>A illustrates the association between <italic toggle="yes">SLC38A4</italic> expression and the infiltration of 22 immune cells. The infiltration of M1 macrophages was positively linked to <italic toggle="yes">SLC38A4</italic> expression, whereas immunosuppressive cells including M2 macrophages, Treg cells, and neutrophils showed a negative association.</p><p id="Par56">Furthermore, the link between <italic toggle="yes">SLC38A4</italic> and immune checkpoint genes was examined. <italic toggle="yes">SLC38A4</italic> exhibited moderate to strong positive correlations with the immunoinhibitors <italic toggle="yes">ARG1</italic> (<italic toggle="yes">R</italic>&#8201;=&#8201;0.89, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;2.2e-16) and <italic toggle="yes">EDNRB</italic> (<italic toggle="yes">R</italic>&#8201;=&#8201;0.56, <italic toggle="yes">p</italic>&#8201;=&#8201;1.5e-15). Conversely, it was negatively linked to the immunostimulator <italic toggle="yes">TNFSF4</italic> (<italic toggle="yes">R</italic> = -0.33, <italic toggle="yes">p</italic>&#8201;=&#8201;1.3e-5) (Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>B).</p><p id="Par57">
<fig id="Fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p>Correlation of SLC38A4 with immune cell infiltration via a lollipop map <bold>A</bold> and immune checkpoint genes such as ARG, EDNRB, and TNFSF4 <bold>B</bold></p></caption><graphic id="d33e1015" position="float" orientation="portrait" xlink:href="12672_2025_3509_Fig7_HTML.jpg"/></fig>
</p></sec><sec id="Sec23"><title>Drug sensitivity analysis of SLC38A4</title><p id="Par58">To assess the viability of <italic toggle="yes">SLC38A4</italic> as a potential treatment target in patients with CRLM, the correlation between IC50 values of anti-neoplastic agents and <italic toggle="yes">SLC38A4</italic> expression was investigated. Classical chemotherapy agents such as 5-fluorouracil, docetaxel, and paclitaxel, along with novel targeted therapies including lapatinib, trametinib, and the Wee1 inhibitor, were positively correlated with <italic toggle="yes">SLC38A4</italic> expression (Fig.&#160;<xref rid="Fig8" ref-type="fig">8</xref>). Supplementary Table 3 presents the correlation analysis data for all evaluated drugs.</p><p id="Par59">
<fig id="Fig8" position="float" orientation="portrait"><label>Fig. 8</label><caption><p>Scatter plot of the correlation between multiple anti-tumor drugs and the expression of SLC38A4</p></caption><graphic id="d33e1041" position="float" orientation="portrait" xlink:href="12672_2025_3509_Fig8_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec24"><title>Discussion</title><p id="Par60">CRLM is the leading site for metastasis and the main factor for mortality associated with CRC. However, therapeutic strategies for CRLM yield unsatisfactory clinical outcomes [<xref ref-type="bibr" rid="CR37">37</xref>]. Systemic treatment, particularly targeted therapies, is limited by the lack of accurate prognostic and therapeutic biomarkers [<xref ref-type="bibr" rid="CR38">38</xref>]. Biomarkers are central to predicting disease prognosis, monitoring disease progression and treatment efficacy, and screening appropriate treatment options [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Nonetheless, biomarkers that truly reflect the situation of liver metastasis in CRLM are scarce. This study identified MRDEGs, conducted a prognostic analysis based on their expression in CRLM tissues, and elucidated the role of <italic toggle="yes">SLC38A4</italic> in CRLM. These findings may illuminate the prognostic significance of <italic toggle="yes">SLC38A4</italic>, positioning it as a potential biomarker for future therapeutic investigations in CRLM.</p><p id="Par61">Initially, 169 MRDEGs were screened, and their prognostic impact on CRLM was investigated. To identify precise prognostic biomarkers that accurately reflect the true condition of CRLM, <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE159216">GSE159216</ext-link> was selected as the CRLM cohort for further analysis [<xref ref-type="bibr" rid="CR18">18</xref>]. It includes both gene expression profiles of CRLM tissues and corresponding survival data. Cox regression analyses identified nine MRDEGs, including <italic toggle="yes">SLC38A4</italic>, <italic toggle="yes">RBKS</italic>, <italic toggle="yes">ASPA</italic>, <italic toggle="yes">CTH</italic>, <italic toggle="yes">ENPP1</italic>, <italic toggle="yes">TF</italic>, <italic toggle="yes">CYP39A1</italic>, <italic toggle="yes">G6PC</italic>, and <italic toggle="yes">FOM3</italic>, as independent predictors of CRLM prognosis. Furthermore, Kaplan-Meier survival analysis suggested that only <italic toggle="yes">SLC38A4</italic> and <italic toggle="yes">G6PC</italic> serve as prognostic biomarkers associated with favorable OS. Notably, <italic toggle="yes">SLC38A4</italic> outperformed <italic toggle="yes">G6PC</italic> in prognostic power, survival prediction potential, diagnostic discrimination, and liver-specific biological relevance. Given these advantages, <italic toggle="yes">SLC38A4</italic> was selected as the primary focus for subsequent investigation.</p><p id="Par62">The differential expression of SLC38A4 between CRLM and NL was validated through GEO datasets, qRT-PCR, WB, and IHC experiments. The <italic toggle="yes">SLC38A4</italic>-encoded protein is predominantly expressed in human liver tissues [<xref ref-type="bibr" rid="CR34">34</xref>], consistent with our findings. Within the tumor, SLC38A4 exhibited predominantly membranous and cytoplasmic staining, reflecting its role in transporting amino acids [<xref ref-type="bibr" rid="CR22">22</xref>]. Furthermore, the expression of SLC38A4 was downregulated in CRLM tissues compared to NL tissues. These findings have not been previously reported in CRLM. Additionally, SLC38A4 expression was silenced in HCC compared to NL tissues [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>], aligning with our findings.</p><p id="Par63">To obtain deeper insights into the role of <italic toggle="yes">SLC38A4</italic> and its interacting partners in CRLM, GO and KEGG analyses were conducted. <italic toggle="yes">SLC38A4</italic> and its correlated genes predominantly participate in diverse metabolic processes and pathways. Furthermore, GSEA findings suggested that high expression of <italic toggle="yes">SLC38A4</italic> is linked to numerous metabolic pathways for various substrates. Abnormalities in cancer metabolism are one of the key cancer hallmarks [<xref ref-type="bibr" rid="CR41">41</xref>]. Metabolic reprogramming contributes to tumor initiation, progression, and metastasis [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Moreover, metabolic contributions from metastatic sites are important drivers of colonization and outgrowth by disseminated cancer cells [<xref ref-type="bibr" rid="CR44">44</xref>]. For CRLM, hepatic metastatic CRC cells can reprogram metabolic pathways through substances, such as <italic toggle="yes">ALDOB</italic> and exosomal <italic toggle="yes">HSPC111</italic>, promoting colonization and outgrowth [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Our findings indicated that <italic toggle="yes">SLC38A4</italic> may mediate metabolic reprogramming in the liver, consistent with previous studies [<xref ref-type="bibr" rid="CR44">44</xref>&#8211;<xref ref-type="bibr" rid="CR46">46</xref>]. Contrarily, <italic toggle="yes">SLC38A4</italic> may serve as a suppressor, inhibiting CRLM progression. Additional mechanistic investigations are required to determine the function of <italic toggle="yes">SLC38A4</italic> in CRLM.</p><p id="Par64">The TME consists of various types of cells that interact with tumor cells [<xref ref-type="bibr" rid="CR47">47</xref>]. It is central to tumor genesis, progression, invasion, and metastasis [<xref ref-type="bibr" rid="CR48">48</xref>&#8211;<xref ref-type="bibr" rid="CR50">50</xref>]. Modulating the balance between tumor-promoting and tumor-inhibiting immune cells within the TME holds promise for cancer treatment. Our study indicated that the expression of <italic toggle="yes">SLC38A4</italic> positively correlates with M1 macrophage infiltration but negatively correlates with M2 macrophages, Treg cells, and neutrophils. M1 macrophages exert anti-tumor effects, while M2 macrophages promote tumor growth [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. Treg cells suppress tumor-specific immune responses [<xref ref-type="bibr" rid="CR53">53</xref>], and neutrophils promote the proliferation and metastasis of cancer cells via multiple pathways [<xref ref-type="bibr" rid="CR54">54</xref>]. Additionally, the links between <italic toggle="yes">SLC38A4</italic> and immune checkpoint genes were investigated. <italic toggle="yes">SLC38A4</italic> was positively associated with <italic toggle="yes">ARG1</italic> and <italic toggle="yes">EDNRB</italic>, while it was negatively associated with <italic toggle="yes">TNFSF4</italic>. <italic toggle="yes">ARG1</italic> promotes tumor immune evasion by depleting L-arginine in the TME, leading to T cell dysfunction [<xref ref-type="bibr" rid="CR55">55</xref>]. <italic toggle="yes">EDNRB</italic> functions as an immune regulator within the TME, contributing to immune evasion and angiogenesis via tumor-associated macrophages [<xref ref-type="bibr" rid="CR56">56</xref>]. Paradoxically, EDNRB overexpression inhibits proliferation and migration of prostate cancer cells through activation of the cGMP-PKG pathway [<xref ref-type="bibr" rid="CR57">57</xref>]. <italic toggle="yes">TNFSF4</italic> (<italic toggle="yes">OX40L</italic>) is a critical co-stimulatory molecule for T cell activation and adaptive immunity. <italic toggle="yes">OX40</italic>/<italic toggle="yes">OX40L</italic> signaling enhances T cell functions, counteracts Treg suppression, and boosts anti-tumor immunity [<xref ref-type="bibr" rid="CR58">58</xref>]. Collectively, <italic toggle="yes">SLC38A4</italic> is significantly linked to the infiltration of immune cells and key immune checkpoint genes, suggesting its potential role in modulating the immune landscape of the TME.</p><p id="Par65">Drug resistance remains a primary contributor to deaths caused by cancer [<xref ref-type="bibr" rid="CR59">59</xref>]. Advances in genome-wide screening methods have elucidated the evolution of tumor responses to therapeutic interventions, providing novel insights to mitigate drug resistance and improve treatment efficacy [<xref ref-type="bibr" rid="CR60">60</xref>]. Various anti-tumor drugs, including conventional chemotherapy agents like 5-fluorouracil, docetaxel, and paclitaxel, as well as novel targeted therapies such as lapatinib, trametinib, and Wee1 inhibitor, have demonstrated therapeutic efficacy against various malignancies, including CRC and CRLM [<xref ref-type="bibr" rid="CR61">61</xref>&#8211;<xref ref-type="bibr" rid="CR63">63</xref>]. Our research demonstrated that the effectiveness of these agents was positively connected to the upregulation of <italic toggle="yes">SLC38A4</italic>. Therefore, targeting <italic toggle="yes">SLC38A4</italic> could potentially enhance the efficacy of these drugs in treating CRLM. However, the mechanisms behind these correlations warrant further investigation.</p><p id="Par66">To our knowledge, this research is the first to investigate the function of <italic toggle="yes">SLC38A4</italic> in patients with CRLM. <italic toggle="yes">SLC38A4</italic> acts as a favorable prognostic biomarker with mechanisms connected to metabolic reprogramming and immune cell infiltration. Therefore, <italic toggle="yes">SLC38A4</italic> may be a potential biomarker for future therapeutic investigation. However, the research has specific limitations. Firstly, our analysis was limited to one CRLM dataset (<ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE159216">GSE159216</ext-link>), as it was the only resource meeting our criteria: transcriptomic profiles from CRLM tissues and matched survival data. To offer additional context, we validated findings in primary CRC using the TCGA-COADREAD dataset, where high <italic toggle="yes">SLC38A4</italic> expression similarly showed favorable prognostic significance (Fig. <xref rid="MOESM3" ref-type="media">S3</xref>). While biological differences between primary and liver metastatic lesions exist, this reinforces <italic toggle="yes">SLC38A4</italic>&#8217;s prognostic implication. Future studies will include additional CRLM cohorts for further validation of our findings. Secondly, this bioinformatics-driven research provides a preliminary understanding of <italic toggle="yes">SLC38A4</italic>&#8217;s role in CRLM; however, its detailed molecular mechanisms are still unclear and require further experimental functional verification (e.g., knockdown or overexpression). This issue will be addressed in our upcoming research. Lastly, the absence of multiple testing correction in immune cell correlations and drug sensitivity analyses may increase the risk of false positives. We will validate the findings through experimental approaches.</p></sec><sec id="Sec25"><title>Conclusion</title><p id="Par67">The research indicated the significance of <italic toggle="yes">SLC38A4</italic> in the prognosis and biological aspects of CRLM. <italic toggle="yes">SLC38A4</italic> is related to a favorable prognosis in CRLM patients, potentially through its impact on immune infiltration. Thus, <italic toggle="yes">SLC38A4</italic> may function as a prognostic biomarker and a potential candidate for future therapeutic investigation, providing a novel perspective on precision oncology for patients with CRLM.</p></sec><sec id="Sec26" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="12672_2025_3509_MOESM1_ESM.xlsx" position="float" orientation="portrait"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xlink:href="12672_2025_3509_MOESM2_ESM.xlsx" position="float" orientation="portrait"><caption><p>Supplementary Material 2.</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xlink:href="12672_2025_3509_MOESM3_ESM.xlsx" position="float" orientation="portrait"><caption><p>Supplementary Material 3.</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM4" position="float" orientation="portrait"><media xlink:href="12672_2025_3509_MOESM4_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 4.</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM5" position="float" orientation="portrait"><media xlink:href="12672_2025_3509_MOESM5_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 5.</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM6" position="float" orientation="portrait"><media xlink:href="12672_2025_3509_MOESM6_ESM.tif" position="float" orientation="portrait"><caption><p>Supplementary Material 6.</p></caption></media></supplementary-material>
</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CRLM</term><def><p id="Par5">Colorectal liver metastases</p></def></def-item><def-item><term>NL</term><def><p id="Par6">Normal liver</p></def></def-item><def-item><term>CRC</term><def><p id="Par7">Colorectal cancer</p></def></def-item><def-item><term>HCC</term><def><p id="Par8">Hepatocellular carcinoma</p></def></def-item><def-item><term>IHC</term><def><p id="Par9">Immunohistochemistry</p></def></def-item><def-item><term>OS</term><def><p id="Par10">Overall survival</p></def></def-item><def-item><term>GEO</term><def><p id="Par11">Gene Expression Omnibus</p></def></def-item><def-item><term>DEGs</term><def><p id="Par12">Differentially expressed genes</p></def></def-item><def-item><term>MRGs</term><def><p id="Par13">Metabolism-related genes</p></def></def-item><def-item><term>MRDEGs</term><def><p id="Par14">Metabolism-related differentially expressed genes</p></def></def-item><def-item><term>WGCNA</term><def><p id="Par15">Weighted gene co-expression network analysis</p></def></def-item><def-item><term>GO</term><def><p id="Par16">Gene Ontology</p></def></def-item><def-item><term>MF</term><def><p id="Par17">Molecular function</p></def></def-item><def-item><term>CC</term><def><p id="Par18">Cellular components</p></def></def-item><def-item><term>BP</term><def><p id="Par19">Biological processes</p></def></def-item><def-item><term>GSEA</term><def><p id="Par20">Gene set enrichment analysis</p></def></def-item><def-item><term>KEGG</term><def><p id="Par21">Kyoto Encyclopedia of Genes and Genomes</p></def></def-item><def-item><term>TME</term><def><p id="Par22">Tumor microenvironment</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>Ying Liu helped write the manuscript. Xin Wei was responsible for sample collection and experiments. Ningning Chen collected data and conducted statistical analysis. Weijia Wang conducted the research and revised the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The research was supported by The Beijing Xisike Clinical Oncology Research Foundation (Y-HH202101-0234).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The gene expression data analyzed in this study were sourced from public repositories. The datasets can be accessed via the Gene Expression Omnibus (GEO) under accession numbers <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE38174">GSE38174</ext-link>, <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE41258">GSE41258</ext-link>, and <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE159216">GSE159216</ext-link> (https:/www.ncbi.nlm.nih.gov/geo), and The Cancer Genome Atlas (TCGA) colon and rectal cancer (TCGA-COADREAD) project ( https://portal.gdc.cancer.gov ).</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par68">This study was conducted in strict alignment with the ethical principles and guidelines of the Declaration of Helsinki. The Ethics Committee at Shaanxi Provincial People&#8217;s Hospital granted approval for this research (Ethical Number: 2023-R156). The study obtained written informed consent from all patients for their participation.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par69">All authors have reviewed the manuscript and consented to its publication.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par70">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>F</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M</given-names></name><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name><etal/></person-group><article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2024</year><volume>74</volume><issue>3</issue><fpage>229</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.3322/caac.21834</pub-id><pub-id pub-id-type="pmid">38572751</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229&#8211;63. 10.3322/caac.21834.<pub-id pub-id-type="pmid">38572751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21834</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>X</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Liver metastasis from colorectal cancer: pathogenetic development, immune landscape of the tumour microenvironment and therapeutic approaches</article-title><source>J Experimental Clin Cancer Research: CR</source><year>2023</year><volume>42</volume><issue>1</issue><fpage>177</fpage><pub-id pub-id-type="doi">10.1186/s13046-023-02729-7</pub-id><pub-id pub-id-type="pmcid">PMC10362774</pub-id><pub-id pub-id-type="pmid">37480104</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Wang Y, Zhong X, He X, Hu Z, Huang H, Chen J, et al. Liver metastasis from colorectal cancer: pathogenetic development, immune landscape of the tumour microenvironment and therapeutic approaches. J Experimental Clin Cancer Research: CR. 2023;42(1):177. 10.1186/s13046-023-02729-7.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-023-02729-7</pub-id><pub-id pub-id-type="pmcid">PMC10362774</pub-id><pub-id pub-id-type="pmid">37480104</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsilimigras</surname><given-names>DI</given-names></name><name name-style="western"><surname>Brodt</surname><given-names>P</given-names></name><name name-style="western"><surname>Clavien</surname><given-names>PA</given-names></name><name name-style="western"><surname>Muschel</surname><given-names>RJ</given-names></name><name name-style="western"><surname>D&#8217;Angelica</surname><given-names>MI</given-names></name><name name-style="western"><surname>Endo</surname><given-names>I</given-names></name><etal/></person-group><article-title>Liver metastases</article-title><source>Nat Reviews Disease Primers</source><year>2021</year><volume>7</volume><issue>1</issue><fpage>27</fpage><pub-id pub-id-type="doi">10.1038/s41572-021-00261-6</pub-id><pub-id pub-id-type="pmid">33859205</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Tsilimigras DI, Brodt P, Clavien PA, Muschel RJ, D&#8217;Angelica MI, Endo I, et al. Liver metastases. Nat Reviews Disease Primers. 2021;7(1):27. 10.1038/s41572-021-00261-6.<pub-id pub-id-type="pmid">33859205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-021-00261-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>J</given-names></name><name name-style="western"><surname>Petrillo</surname><given-names>A</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>EC</given-names></name><name name-style="western"><surname>Shaida</surname><given-names>N</given-names></name><name name-style="western"><surname>Khwaja</surname><given-names>S</given-names></name><name name-style="western"><surname>Cheow</surname><given-names>HK</given-names></name><etal/></person-group><article-title>Colorectal liver metastases: current management and future perspectives</article-title><source>World J Clin Oncol</source><year>2020</year><volume>11</volume><issue>10</issue><fpage>761</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.5306/wjco.v11.i10.761</pub-id><pub-id pub-id-type="pmid">33200074</pub-id><pub-id pub-id-type="pmcid">PMC7643190</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Martin J, Petrillo A, Smyth EC, Shaida N, Khwaja S, Cheow HK, et al. Colorectal liver metastases: current management and future perspectives. World J Clin Oncol. 2020;11(10):761&#8211;808. 10.5306/wjco.v11.i10.761.<pub-id pub-id-type="pmid">33200074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5306/wjco.v11.i10.761</pub-id><pub-id pub-id-type="pmcid">PMC7643190</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Cutsem</surname><given-names>E</given-names></name><name name-style="western"><surname>Cervantes</surname><given-names>A</given-names></name><name name-style="western"><surname>Adam</surname><given-names>R</given-names></name><name name-style="western"><surname>Sobrero</surname><given-names>A</given-names></name><name name-style="western"><surname>Van Krieken</surname><given-names>JH</given-names></name><name name-style="western"><surname>Aderka</surname><given-names>D</given-names></name><etal/></person-group><article-title>ESMO consensus guidelines for the management of patients with metastatic colorectal cancer</article-title><source>Annals Oncology: Official J Eur Soc Med Oncol</source><year>2016</year><volume>27</volume><issue>8</issue><fpage>1386</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdw235</pub-id><pub-id pub-id-type="pmid">27380959</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals Oncology: Official J Eur Soc Med Oncol. 2016;27(8):1386&#8211;422. 10.1093/annonc/mdw235.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdw235</pub-id><pub-id pub-id-type="pmid">27380959</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al Bandar</surname><given-names>MH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>NK</given-names></name></person-group><article-title>Current status and future perspectives on treatment of liver metastasis in colorectal cancer (Review)</article-title><source>Oncol Rep</source><year>2017</year><volume>37</volume><issue>5</issue><fpage>2553</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.3892/or.2017.5531</pub-id><pub-id pub-id-type="pmid">28350137</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Al Bandar MH, Kim NK. Current status and future perspectives on treatment of liver metastasis in colorectal cancer (Review). Oncol Rep. 2017;37(5):2553&#8211;64. 10.3892/or.2017.5531.<pub-id pub-id-type="pmid">28350137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2017.5531</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imai</surname><given-names>K</given-names></name><name name-style="western"><surname>Adam</surname><given-names>R</given-names></name><name name-style="western"><surname>Baba</surname><given-names>H</given-names></name></person-group><article-title>How to increase the resectability of initially unresectable colorectal liver metastases: A surgical perspective</article-title><source>Annals Gastroenterological Surg</source><year>2019</year><volume>3</volume><issue>5</issue><fpage>476</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1002/ags3.12276</pub-id><pub-id pub-id-type="pmcid">PMC6749948</pub-id><pub-id pub-id-type="pmid">31549007</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Imai K, Adam R, Baba H. How to increase the resectability of initially unresectable colorectal liver metastases: A surgical perspective. Annals Gastroenterological Surg. 2019;3(5):476&#8211;86. 10.1002/ags3.12276.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ags3.12276</pub-id><pub-id pub-id-type="pmcid">PMC6749948</pub-id><pub-id pub-id-type="pmid">31549007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name></person-group><article-title>Methods and biomarkers for early detection, prediction, and diagnosis of colorectal cancer</article-title><source>Biomed pharmacotherapy = Biomedecine Pharmacotherapie</source><year>2023</year><volume>163</volume><fpage>114786</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2023.114786</pub-id><pub-id pub-id-type="pmid">37119736</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Zhang Y, Wang Y, Zhang B, Li P, Zhao Y. Methods and biomarkers for early detection, prediction, and diagnosis of colorectal cancer. Biomed pharmacotherapy = Biomedecine Pharmacotherapie. 2023;163:114786. 10.1016/j.biopha.2023.114786.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2023.114786</pub-id><pub-id pub-id-type="pmid">37119736</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Hewitt DB, Brown ZJ, Pawlik TM. The role of biomarkers in the management of colorectal liver metastases. Cancers. 2022;14(19). 10.3390/cancers14194602.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers14194602</pub-id><pub-id pub-id-type="pmcid">PMC9559307</pub-id><pub-id pub-id-type="pmid">36230522</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Y</given-names></name><etal/></person-group><article-title>THBS1 facilitates colorectal liver metastasis through enhancing epithelial-mesenchymal transition</article-title><source>Clin Translational Oncology: Official Publication Federation Span Oncol Soc Natl Cancer Inst Mexico</source><year>2020</year><volume>22</volume><issue>10</issue><fpage>1730</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1007/s12094-020-02308-8</pub-id><pub-id pub-id-type="pmid">32052380</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Liu X, Xu D, Liu Z, Li Y, Zhang C, Gong Y, et al. THBS1 facilitates colorectal liver metastasis through enhancing epithelial-mesenchymal transition. Clin Translational Oncology: Official Publication Federation Span Oncol Soc Natl Cancer Inst Mexico. 2020;22(10):1730&#8211;40. 10.1007/s12094-020-02308-8.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12094-020-02308-8</pub-id><pub-id pub-id-type="pmid">32052380</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>SM</given-names></name><name name-style="western"><surname>Shen</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>XD</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>SQ</given-names></name><name name-style="western"><surname>Shi</surname><given-names>LL</given-names></name><etal/></person-group><article-title>Identification of hub genes for colorectal cancer with liver metastasis using miRNA-mRNA network</article-title><source>Dis Markers</source><year>2023</year><volume>2023</volume><fpage>2295788</fpage><pub-id pub-id-type="doi">10.1155/2023/2295788</pub-id><pub-id pub-id-type="pmid">36798788</pub-id><pub-id pub-id-type="pmcid">PMC9928517</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Zhang SM, Shen C, Li J, Wang XD, Zhai SQ, Shi LL, et al. Identification of hub genes for colorectal cancer with liver metastasis using miRNA-mRNA network. Dis Markers. 2023;2023:2295788. 10.1155/2023/2295788.<pub-id pub-id-type="pmid">36798788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2023/2295788</pub-id><pub-id pub-id-type="pmcid">PMC9928517</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>L</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X</given-names></name><name name-style="western"><surname>Liang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dai</surname><given-names>X</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Construction of a co-expression network and prediction of metastasis markers in colorectal cancer patients with liver metastasis</article-title><source>J Gastrointest Oncol</source><year>2022</year><volume>13</volume><issue>5</issue><fpage>2426</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.21037/jgo-22-965</pub-id><pub-id pub-id-type="pmid">36388701</pub-id><pub-id pub-id-type="pmcid">PMC9660078</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Lin L, Zeng X, Liang S, Wang Y, Dai X, Sun Y, et al. Construction of a co-expression network and prediction of metastasis markers in colorectal cancer patients with liver metastasis. J Gastrointest Oncol. 2022;13(5):2426&#8211;38. 10.21037/jgo-22-965.<pub-id pub-id-type="pmid">36388701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/jgo-22-965</pub-id><pub-id pub-id-type="pmcid">PMC9660078</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>R</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name></person-group><article-title>Construction and prognostic analysis of miRNA-mRNA regulatory network in liver metastasis from colorectal cancer</article-title><source>World J Surg Oncol</source><year>2021</year><volume>19</volume><issue>1</issue><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/s12957-020-02107-z</pub-id><pub-id pub-id-type="pmid">33397428</pub-id><pub-id pub-id-type="pmcid">PMC7784011</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Cai R, Lu Q, Wang D. Construction and prognostic analysis of miRNA-mRNA regulatory network in liver metastasis from colorectal cancer. World J Surg Oncol. 2021;19(1):7. 10.1186/s12957-020-02107-z.<pub-id pub-id-type="pmid">33397428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12957-020-02107-z</pub-id><pub-id pub-id-type="pmcid">PMC7784011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>Identifying the key genes and MicroRNAs in colorectal cancer liver metastasis by bioinformatics analysis and in vitro experiments</article-title><source>Oncol Rep</source><year>2019</year><volume>41</volume><issue>1</issue><fpage>279</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.3892/or.2018.6840</pub-id><pub-id pub-id-type="pmid">30542696</pub-id><pub-id pub-id-type="pmcid">PMC6278419</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Zhang T, Guo J, Gu J, Wang Z, Wang G, Li H, et al. Identifying the key genes and MicroRNAs in colorectal cancer liver metastasis by bioinformatics analysis and in vitro experiments. Oncol Rep. 2019;41(1):279&#8211;91. 10.3892/or.2018.6840.<pub-id pub-id-type="pmid">30542696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2018.6840</pub-id><pub-id pub-id-type="pmcid">PMC6278419</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Liao</surname><given-names>T</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Identification of IMPA2 as the hub gene associated with colorectal cancer and liver metastasis by integrated bioinformatics analysis</article-title><source>Translational Oncol</source><year>2022</year><volume>21</volume><fpage>101435</fpage><pub-id pub-id-type="doi">10.1016/j.tranon.2022.101435</pub-id><pub-id pub-id-type="pmcid">PMC9136607</pub-id><pub-id pub-id-type="pmid">35483170</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Wang L, Liu D, Liu S, Liao T, Jiao Y, Jiang X, et al. Identification of IMPA2 as the hub gene associated with colorectal cancer and liver metastasis by integrated bioinformatics analysis. Translational Oncol. 2022;21:101435. 10.1016/j.tranon.2022.101435.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tranon.2022.101435</pub-id><pub-id pub-id-type="pmcid">PMC9136607</pub-id><pub-id pub-id-type="pmid">35483170</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>H</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L</given-names></name><name name-style="western"><surname>Xie</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>Complement C5 is a novel biomarker for liver metastasis of colorectal cancer</article-title><source>J Gastrointest Oncol</source><year>2022</year><volume>13</volume><issue>5</issue><fpage>2351</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.21037/jgo-22-829</pub-id><pub-id pub-id-type="pmid">36388659</pub-id><pub-id pub-id-type="pmcid">PMC9660033</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Chang H, Jin L, Xie P, Zhang B, Yu M, Li H, et al. Complement C5 is a novel biomarker for liver metastasis of colorectal cancer. J Gastrointest Oncol. 2022;13(5):2351&#8211;65. 10.21037/jgo-22-829.<pub-id pub-id-type="pmid">36388659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/jgo-22-829</pub-id><pub-id pub-id-type="pmcid">PMC9660033</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Cai</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><etal/></person-group><article-title>Identification of candidate biomarkers and prognostic analysis in colorectal cancer liver metastases</article-title><source>Front Oncol</source><year>2021</year><volume>11</volume><fpage>652354</fpage><pub-id pub-id-type="doi">10.3389/fonc.2021.652354</pub-id><pub-id pub-id-type="pmid">34422629</pub-id><pub-id pub-id-type="pmcid">PMC8371911</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Zhang T, Yuan K, Wang Y, Xu M, Cai S, Chen C, et al. Identification of candidate biomarkers and prognostic analysis in colorectal cancer liver metastases. Front Oncol. 2021;11:652354. 10.3389/fonc.2021.652354.<pub-id pub-id-type="pmid">34422629</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2021.652354</pub-id><pub-id pub-id-type="pmcid">PMC8371911</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>QL</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>ZG</given-names></name><name name-style="western"><surname>Chen</surname><given-names>HN</given-names></name></person-group><article-title>Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment</article-title><source>Cancer Metastasis Rev</source><year>2023</year><pub-id pub-id-type="doi">10.1007/s10555-023-10107-0</pub-id><pub-id pub-id-type="pmid">37061644</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Liu QL, Zhou H, Zhou ZG, Chen HN. Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment. Cancer Metastasis Rev. 2023. 10.1007/s10555-023-10107-0.<pub-id pub-id-type="pmid">37061644</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10555-023-10107-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Clinicopathological and prognostic significance of HER2 status in surgically resected colorectal liver metastases</article-title><source>J Surg Oncol</source><year>2022</year><volume>125</volume><issue>6</issue><fpage>991</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1002/jso.26815</pub-id><pub-id pub-id-type="pmid">35150441</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Han J, Wang X, Zhang C, Wu Q, Ma X, Li Y, et al. Clinicopathological and prognostic significance of HER2 status in surgically resected colorectal liver metastases. J Surg Oncol. 2022;125(6):991&#8211;1001. 10.1002/jso.26815.<pub-id pub-id-type="pmid">35150441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jso.26815</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shigematsu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Inamura</surname><given-names>K</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>N</given-names></name><name name-style="western"><surname>Mise</surname><given-names>Y</given-names></name><name name-style="western"><surname>Saiura</surname><given-names>A</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis</article-title><source>BMC Cancer</source><year>2018</year><volume>18</volume><issue>1</issue><fpage>980</fpage><pub-id pub-id-type="doi">10.1186/s12885-018-4902-8</pub-id><pub-id pub-id-type="pmid">30326864</pub-id><pub-id pub-id-type="pmcid">PMC6192098</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Shigematsu Y, Inamura K, Yamamoto N, Mise Y, Saiura A, Ishikawa Y, et al. Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis. BMC Cancer. 2018;18(1):980. 10.1186/s12885-018-4902-8.<pub-id pub-id-type="pmid">30326864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-018-4902-8</pub-id><pub-id pub-id-type="pmcid">PMC6192098</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Messaoudi</surname><given-names>N</given-names></name><name name-style="western"><surname>Cousineau</surname><given-names>I</given-names></name><name name-style="western"><surname>Arslanian</surname><given-names>E</given-names></name><name name-style="western"><surname>Henault</surname><given-names>D</given-names></name><name name-style="western"><surname>Stephen</surname><given-names>D</given-names></name><name name-style="western"><surname>Vandenbroucke-Menu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Prognostic value of CD73 expression in resected colorectal cancer liver metastasis</article-title><source>Oncoimmunology</source><year>2020</year><volume>9</volume><issue>1</issue><fpage>1746138</fpage><pub-id pub-id-type="doi">10.1080/2162402x.2020.1746138</pub-id><pub-id pub-id-type="pmid">32363113</pub-id><pub-id pub-id-type="pmcid">PMC7185220</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Messaoudi N, Cousineau I, Arslanian E, Henault D, Stephen D, Vandenbroucke-Menu F, et al. Prognostic value of CD73 expression in resected colorectal cancer liver metastasis. Oncoimmunology. 2020;9(1):1746138. 10.1080/2162402x.2020.1746138.<pub-id pub-id-type="pmid">32363113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/2162402X.2020.1746138</pub-id><pub-id pub-id-type="pmcid">PMC7185220</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Q</given-names></name><name name-style="western"><surname>Padmanabhan</surname><given-names>R</given-names></name><name name-style="western"><surname>Villegas</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Gu</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>JX</given-names></name></person-group><article-title>Membrane topological structure of neutral system N/A amino acid transporter 4 (SNAT4) protein</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><issue>44</issue><fpage>38086</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.220277</pub-id><pub-id pub-id-type="pmid">21917917</pub-id><pub-id pub-id-type="pmcid">PMC3207422</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Shi Q, Padmanabhan R, Villegas CJ, Gu S, Jiang JX. Membrane topological structure of neutral system N/A amino acid transporter 4 (SNAT4) protein. J Biol Chem. 2011;286(44):38086&#8211;94. 10.1074/jbc.M111.220277.<pub-id pub-id-type="pmid">21917917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M111.220277</pub-id><pub-id pub-id-type="pmcid">PMC3207422</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Br&#246;er</surname><given-names>S</given-names></name></person-group><article-title>The SLC38 family of sodium-amino acid co-transporters</article-title><source>Pflug Arch: Eur J Physiol</source><year>2014</year><volume>466</volume><issue>1</issue><fpage>155</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1007/s00424-013-1393-y</pub-id><pub-id pub-id-type="pmid">24193407</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Br&#246;er S. The SLC38 family of sodium-amino acid co-transporters. Pflug Arch: Eur J Physiol. 2014;466(1):155&#8211;72. 10.1007/s00424-013-1393-y.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00424-013-1393-y</pub-id><pub-id pub-id-type="pmid">24193407</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>MH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>TT</given-names></name><name name-style="western"><surname>Liu</surname><given-names>XN</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>XT</given-names></name><name name-style="western"><surname>Dai</surname><given-names>YZ</given-names></name><etal/></person-group><article-title>SLC38A4 functions as a tumour suppressor in hepatocellular carcinoma through modulating Wnt/&#946;-catenin/MYC/HMGCS2 axis</article-title><source>Br J Cancer</source><year>2021</year><volume>125</volume><issue>6</issue><fpage>865</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1038/s41416-021-01490-y</pub-id><pub-id pub-id-type="pmid">34274945</pub-id><pub-id pub-id-type="pmcid">PMC8438090</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Li J, Li MH, Wang TT, Liu XN, Zhu XT, Dai YZ, et al. SLC38A4 functions as a tumour suppressor in hepatocellular carcinoma through modulating Wnt/&#946;-catenin/MYC/HMGCS2 axis. Br J Cancer. 2021;125(6):865&#8211;76. 10.1038/s41416-021-01490-y.<pub-id pub-id-type="pmid">34274945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-021-01490-y</pub-id><pub-id pub-id-type="pmcid">PMC8438090</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>HS</given-names></name><name name-style="western"><surname>Na</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Son</surname><given-names>KH</given-names></name><name name-style="western"><surname>Yang</surname><given-names>HD</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SY</given-names></name><name name-style="western"><surname>Shin</surname><given-names>E</given-names></name><etal/></person-group><article-title>ADAR1-dependent miR-3144-3p editing simultaneously induces MSI2 expression and suppresses SLC38A4 expression in liver cancer</article-title><source>Exp Mol Med</source><year>2023</year><volume>55</volume><issue>1</issue><fpage>95</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1038/s12276-022-00916-8</pub-id><pub-id pub-id-type="pmid">36599932</pub-id><pub-id pub-id-type="pmcid">PMC9898302</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Kim HS, Na MJ, Son KH, Yang HD, Kim SY, Shin E, et al. ADAR1-dependent miR-3144-3p editing simultaneously induces MSI2 expression and suppresses SLC38A4 expression in liver cancer. Exp Mol Med. 2023;55(1):95&#8211;107. 10.1038/s12276-022-00916-8.<pub-id pub-id-type="pmid">36599932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s12276-022-00916-8</pub-id><pub-id pub-id-type="pmcid">PMC9898302</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Possemato</surname><given-names>R</given-names></name><name name-style="western"><surname>Marks</surname><given-names>KM</given-names></name><name name-style="western"><surname>Shaul</surname><given-names>YD</given-names></name><name name-style="western"><surname>Pacold</surname><given-names>ME</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D</given-names></name><name name-style="western"><surname>Birsoy</surname><given-names>K</given-names></name><etal/></person-group><article-title>Functional genomics reveal that the Serine synthesis pathway is essential in breast cancer</article-title><source>Nature</source><year>2011</year><volume>476</volume><issue>7360</issue><fpage>346</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1038/nature10350</pub-id><pub-id pub-id-type="pmid">21760589</pub-id><pub-id pub-id-type="pmcid">PMC3353325</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, et al. Functional genomics reveal that the Serine synthesis pathway is essential in breast cancer. Nature. 2011;476(7360):346&#8211;50. 10.1038/nature10350.<pub-id pub-id-type="pmid">21760589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature10350</pub-id><pub-id pub-id-type="pmcid">PMC3353325</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M</given-names></name><etal/></person-group><article-title>Metabolism-associated molecular classification of gastric adenocarcinoma</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>1024985</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.1024985</pub-id><pub-id pub-id-type="pmid">36465405</pub-id><pub-id pub-id-type="pmcid">PMC9709214</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Ye Y, Yang W, Ruan X, Xu L, Cheng W, Zhao M, et al. Metabolism-associated molecular classification of gastric adenocarcinoma. Front Oncol. 2022;12:1024985. 10.3389/fonc.2022.1024985.<pub-id pub-id-type="pmid">36465405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2022.1024985</pub-id><pub-id pub-id-type="pmcid">PMC9709214</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>T</given-names></name><name name-style="western"><surname>Hu</surname><given-names>E</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Guo</surname><given-names>P</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Z</given-names></name><etal/></person-group><article-title>ClusterProfiler 4.0: A universal enrichment tool for interpreting omics data</article-title><source>Innov (Cambridge (Mass))</source><year>2021</year><volume>2</volume><issue>3</issue><fpage>100141</fpage><pub-id pub-id-type="doi">10.1016/j.xinn.2021.100141</pub-id><pub-id pub-id-type="pmcid">PMC8454663</pub-id><pub-id pub-id-type="pmid">34557778</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. ClusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innov (Cambridge (Mass)). 2021;2(3):100141. 10.1016/j.xinn.2021.100141.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xinn.2021.100141</pub-id><pub-id pub-id-type="pmcid">PMC8454663</pub-id><pub-id pub-id-type="pmid">34557778</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newman</surname><given-names>AM</given-names></name><name name-style="western"><surname>Liu</surname><given-names>CL</given-names></name><name name-style="western"><surname>Green</surname><given-names>MR</given-names></name><name name-style="western"><surname>Gentles</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Feng</surname><given-names>W</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Robust enumeration of cell subsets from tissue expression profiles</article-title><source>Nat Methods</source><year>2015</year><volume>12</volume><issue>5</issue><fpage>453</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3337</pub-id><pub-id pub-id-type="pmid">25822800</pub-id><pub-id pub-id-type="pmcid">PMC4739640</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453&#8211;7. 10.1038/nmeth.3337.<pub-id pub-id-type="pmid">25822800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmeth.3337</pub-id><pub-id pub-id-type="pmcid">PMC4739640</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thorsson</surname><given-names>V</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>DL</given-names></name><name name-style="western"><surname>Brown</surname><given-names>SD</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>D</given-names></name><name name-style="western"><surname>Bortone</surname><given-names>DS</given-names></name><name name-style="western"><surname>Ou Yang</surname><given-names>TH</given-names></name><etal/></person-group><article-title>The immune landscape of cancer</article-title><source>Immunity</source><year>2018</year><volume>48</volume><issue>4</issue><fpage>812</fpage><lpage>e3014</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.03.023</pub-id><pub-id pub-id-type="pmid">29628290</pub-id><pub-id pub-id-type="pmcid">PMC5982584</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The immune landscape of cancer. Immunity. 2018;48(4):812&#8211;e3014. 10.1016/j.immuni.2018.03.023.<pub-id pub-id-type="pmid">29628290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2018.03.023</pub-id><pub-id pub-id-type="pmcid">PMC5982584</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>W</given-names></name><name name-style="western"><surname>Soares</surname><given-names>J</given-names></name><name name-style="western"><surname>Greninger</surname><given-names>P</given-names></name><name name-style="western"><surname>Edelman</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Lightfoot</surname><given-names>H</given-names></name><name name-style="western"><surname>Forbes</surname><given-names>S</given-names></name><etal/></person-group><article-title>Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells</article-title><source>Nucleic Acids Res</source><year>2013</year><volume>41</volume><issue>Database issue</issue><fpage>D955</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1111</pub-id><pub-id pub-id-type="pmid">23180760</pub-id><pub-id pub-id-type="pmcid">PMC3531057</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41(Database issue):D955&#8211;61. 10.1093/nar/gks1111.<pub-id pub-id-type="pmid">23180760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gks1111</pub-id><pub-id pub-id-type="pmcid">PMC3531057</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Maeser D, Gruener RF, Huang RS. OncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22(6). 10.1093/bib/bbab260.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bib/bbab260</pub-id><pub-id pub-id-type="pmcid">PMC8574972</pub-id><pub-id pub-id-type="pmid">34260682</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varghese</surname><given-names>F</given-names></name><name name-style="western"><surname>Bukhari</surname><given-names>AB</given-names></name><name name-style="western"><surname>Malhotra</surname><given-names>R</given-names></name><name name-style="western"><surname>De</surname><given-names>A</given-names></name></person-group><article-title>IHC profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><issue>5</issue><fpage>e96801</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0096801</pub-id><pub-id pub-id-type="pmid">24802416</pub-id><pub-id pub-id-type="pmcid">PMC4011881</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Varghese F, Bukhari AB, Malhotra R, De A. IHC profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS ONE. 2014;9(5):e96801. 10.1371/journal.pone.0096801.<pub-id pub-id-type="pmid">24802416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0096801</pub-id><pub-id pub-id-type="pmcid">PMC4011881</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatanaka</surname><given-names>T</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name><name name-style="western"><surname>Ling</surname><given-names>R</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>PD</given-names></name><name name-style="western"><surname>Sugawara</surname><given-names>M</given-names></name><name name-style="western"><surname>Leibach</surname><given-names>FH</given-names></name><etal/></person-group><article-title>Evidence for the transport of neutral as well as cationic amino acids by ATA3, a novel and liver-specific subtype of amino acid transport system A</article-title><source>Biochim Biophys Acta</source><year>2001</year><volume>1510</volume><issue>1&#8211;2</issue><fpage>10</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/s0005-2736(00)00390-4</pub-id><pub-id pub-id-type="pmid">11342143</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Hatanaka T, Huang W, Ling R, Prasad PD, Sugawara M, Leibach FH, et al. Evidence for the transport of neutral as well as cationic amino acids by ATA3, a novel and liver-specific subtype of amino acid transport system A. Biochim Biophys Acta. 2001;1510(1&#8211;2):10&#8211;7. 10.1016/s0005-2736(00)00390-4.<pub-id pub-id-type="pmid">11342143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0005-2736(00)00390-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Leary</surname><given-names>K</given-names></name></person-group><article-title>Liver metastases cultivate an immune desert</article-title><source>Nat Rev Cancer</source><year>2021</year><volume>21</volume><issue>3</issue><fpage>143</fpage><pub-id pub-id-type="doi">10.1038/s41568-021-00338-0</pub-id><pub-id pub-id-type="pmid">33547456</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">O&#8217;Leary K. Liver metastases cultivate an immune desert. Nat Rev Cancer. 2021;21(3):143. 10.1038/s41568-021-00338-0.<pub-id pub-id-type="pmid">33547456</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-021-00338-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Liu Y, Zhang Q, Xing B, Luo N, Gao R, Yu K et al. Immune phenotypic linkage between colorectal cancer and liver metastasis. Cancer cell. 2022;40(4):424&#8201;&#8211;&#8201;37.e5. 10.1016/j.ccell.2022.02.013<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2022.02.013</pub-id><pub-id pub-id-type="pmid">35303421</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nordlinger</surname><given-names>B</given-names></name><name name-style="western"><surname>Sorbye</surname><given-names>H</given-names></name><name name-style="western"><surname>Glimelius</surname><given-names>B</given-names></name><name name-style="western"><surname>Poston</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Schlag</surname><given-names>PM</given-names></name><name name-style="western"><surname>Rougier</surname><given-names>P</given-names></name><etal/></person-group><article-title>Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial</article-title><source>Lancet Oncol</source><year>2013</year><volume>14</volume><issue>12</issue><fpage>1208</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/s1470-2045(13)70447-9</pub-id><pub-id pub-id-type="pmid">24120480</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208&#8211;15. 10.1016/s1470-2045(13)70447-9.<pub-id pub-id-type="pmid">24120480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(13)70447-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wen</surname><given-names>X</given-names></name><name name-style="western"><surname>Amador</surname><given-names>EH</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>L</given-names></name><etal/></person-group><article-title>Colorectal liver metastasis: molecular mechanism and interventional therapy</article-title><source>Signal Transduct Target Ther</source><year>2022</year><volume>7</volume><issue>1</issue><fpage>70</fpage><pub-id pub-id-type="doi">10.1038/s41392-022-00922-2</pub-id><pub-id pub-id-type="pmid">35246503</pub-id><pub-id pub-id-type="pmcid">PMC8897452</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Zhou H, Liu Z, Wang Y, Wen X, Amador EH, Yuan L, et al. Colorectal liver metastasis: molecular mechanism and interventional therapy. Signal Transduct Target Ther. 2022;7(1):70. 10.1038/s41392-022-00922-2.<pub-id pub-id-type="pmid">35246503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-022-00922-2</pub-id><pub-id pub-id-type="pmcid">PMC8897452</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martelli</surname><given-names>V</given-names></name><name name-style="western"><surname>Pastorino</surname><given-names>A</given-names></name><name name-style="western"><surname>Sobrero</surname><given-names>AF</given-names></name></person-group><article-title>Prognostic and predictive molecular biomarkers in advanced colorectal cancer</article-title><source>Pharmacol Ther</source><year>2022</year><volume>236</volume><fpage>108239</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2022.108239</pub-id><pub-id pub-id-type="pmid">35780916</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Martelli V, Pastorino A, Sobrero AF. Prognostic and predictive molecular biomarkers in advanced colorectal cancer. Pharmacol Ther. 2022;236:108239. 10.1016/j.pharmthera.2022.108239.<pub-id pub-id-type="pmid">35780916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2022.108239</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>G</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Ill&#225;n</surname><given-names>E</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>L</given-names></name><name name-style="western"><surname>Balaguer</surname><given-names>F</given-names></name><name name-style="western"><surname>Goel</surname><given-names>A</given-names></name></person-group><article-title>Epigenetics of colorectal cancer: biomarker and therapeutic potential</article-title><source>Nat Reviews Gastroenterol Hepatol</source><year>2020</year><volume>17</volume><issue>2</issue><fpage>111</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1038/s41575-019-0230-y</pub-id><pub-id pub-id-type="pmcid">PMC7228650</pub-id><pub-id pub-id-type="pmid">31900466</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Jung G, Hern&#225;ndez-Ill&#225;n E, Moreira L, Balaguer F, Goel A. Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Reviews Gastroenterol Hepatol. 2020;17(2):111&#8211;30. 10.1038/s41575-019-0230-y.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41575-019-0230-y</pub-id><pub-id pub-id-type="pmcid">PMC7228650</pub-id><pub-id pub-id-type="pmid">31900466</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanahan</surname><given-names>D</given-names></name><name name-style="western"><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>Hallmarks of cancer: the next generation</article-title><source>Cell</source><year>2011</year><volume>144</volume><issue>5</issue><fpage>646</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646&#8211;74. 10.1016/j.cell.2011.02.013.<pub-id pub-id-type="pmid">21376230</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2011.02.013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoshida</surname><given-names>GJ</given-names></name></person-group><article-title>Metabolic reprogramming: the emerging concept and associated therapeutic strategies</article-title><source>J Experimental Clin Cancer Research: CR</source><year>2015</year><volume>34</volume><fpage>111</fpage><pub-id pub-id-type="doi">10.1186/s13046-015-0221-y</pub-id><pub-id pub-id-type="pmcid">PMC4595070</pub-id><pub-id pub-id-type="pmid">26445347</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Yoshida GJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Experimental Clin Cancer Research: CR. 2015;34:111. 10.1186/s13046-015-0221-y.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-015-0221-y</pub-id><pub-id pub-id-type="pmcid">PMC4595070</pub-id><pub-id pub-id-type="pmid">26445347</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;nez-Reyes</surname><given-names>I</given-names></name><name name-style="western"><surname>Chandel</surname><given-names>NS</given-names></name></person-group><article-title>Cancer metabolism: looking forward</article-title><source>Nat Rev Cancer</source><year>2021</year><volume>21</volume><issue>10</issue><fpage>669</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1038/s41568-021-00378-6</pub-id><pub-id pub-id-type="pmid">34272515</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Mart&#237;nez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669&#8211;80. 10.1038/s41568-021-00378-6.<pub-id pub-id-type="pmid">34272515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-021-00378-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganguly</surname><given-names>K</given-names></name><name name-style="western"><surname>Kimmelman</surname><given-names>AC</given-names></name></person-group><article-title>Reprogramming of tissue metabolism during cancer metastasis</article-title><source>Trends Cancer</source><year>2023</year><volume>9</volume><issue>6</issue><fpage>461</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2023.02.005</pub-id><pub-id pub-id-type="pmid">36935322</pub-id><pub-id pub-id-type="pmcid">PMC10192089</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Ganguly K, Kimmelman AC. Reprogramming of tissue metabolism during cancer metastasis. Trends Cancer. 2023;9(6):461&#8211;71. 10.1016/j.trecan.2023.02.005.<pub-id pub-id-type="pmid">36935322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trecan.2023.02.005</pub-id><pub-id pub-id-type="pmcid">PMC10192089</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bu</surname><given-names>P</given-names></name><name name-style="western"><surname>Chen</surname><given-names>KY</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>K</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>C</given-names></name><name name-style="western"><surname>Crown</surname><given-names>SB</given-names></name><name name-style="western"><surname>Rakhilin</surname><given-names>N</given-names></name><etal/></person-group><article-title>Aldolase B-Mediated Fructose metabolism drives metabolic reprogramming of colon cancer liver metastasis</article-title><source>Cell Metabol</source><year>2018</year><volume>27</volume><issue>6</issue><fpage>1249</fpage><lpage>e624</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.04.003</pub-id><pub-id pub-id-type="pmcid">PMC5990465</pub-id><pub-id pub-id-type="pmid">29706565</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Bu P, Chen KY, Xiang K, Johnson C, Crown SB, Rakhilin N, et al. Aldolase B-Mediated Fructose metabolism drives metabolic reprogramming of colon cancer liver metastasis. Cell Metabol. 2018;27(6):1249&#8211;e624. 10.1016/j.cmet.2018.04.003.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2018.04.003</pub-id><pub-id pub-id-type="pmcid">PMC5990465</pub-id><pub-id pub-id-type="pmid">29706565</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>XY</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>He</surname><given-names>TC</given-names></name><name name-style="western"><surname>Han</surname><given-names>JH</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><etal/></person-group><article-title>Cancer-derived Exosomal HSPC111 promotes colorectal cancer liver metastasis by reprogramming lipid metabolism in cancer-associated fibroblasts</article-title><source>Cell Death Dis</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>57</fpage><pub-id pub-id-type="doi">10.1038/s41419-022-04506-4</pub-id><pub-id pub-id-type="pmid">35027547</pub-id><pub-id pub-id-type="pmcid">PMC8758774</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Zhang C, Wang XY, Zhang P, He TC, Han JH, Zhang R, et al. Cancer-derived Exosomal HSPC111 promotes colorectal cancer liver metastasis by reprogramming lipid metabolism in cancer-associated fibroblasts. Cell Death Dis. 2022;13(1):57. 10.1038/s41419-022-04506-4.<pub-id pub-id-type="pmid">35027547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-022-04506-4</pub-id><pub-id pub-id-type="pmcid">PMC8758774</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glaviano</surname><given-names>A</given-names></name><name name-style="western"><surname>Lau</surname><given-names>HS</given-names></name><name name-style="western"><surname>Carter</surname><given-names>LM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>EHC</given-names></name><name name-style="western"><surname>Lam</surname><given-names>HY</given-names></name><name name-style="western"><surname>Okina</surname><given-names>E</given-names></name><etal/></person-group><article-title>Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition</article-title><source>J Hematol Oncol</source><year>2025</year><volume>18</volume><issue>1</issue><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/s13045-024-01634-6</pub-id><pub-id pub-id-type="pmid">39806516</pub-id><pub-id pub-id-type="pmcid">PMC11733683</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Glaviano A, Lau HS, Carter LM, Lee EHC, Lam HY, Okina E, et al. Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition. J Hematol Oncol. 2025;18(1):6. 10.1186/s13045-024-01634-6.<pub-id pub-id-type="pmid">39806516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-024-01634-6</pub-id><pub-id pub-id-type="pmcid">PMC11733683</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spill</surname><given-names>F</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>DS</given-names></name><name name-style="western"><surname>Kamm</surname><given-names>RD</given-names></name><name name-style="western"><surname>Zaman</surname><given-names>MH</given-names></name></person-group><article-title>Impact of the physical microenvironment on tumor progression and metastasis</article-title><source>Curr Opin Biotechnol</source><year>2016</year><volume>40</volume><fpage>41</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2016.02.007</pub-id><pub-id pub-id-type="pmid">26938687</pub-id><pub-id pub-id-type="pmcid">PMC4975620</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Spill F, Reynolds DS, Kamm RD, Zaman MH. Impact of the physical microenvironment on tumor progression and metastasis. Curr Opin Biotechnol. 2016;40:41&#8211;8. 10.1016/j.copbio.2016.02.007.<pub-id pub-id-type="pmid">26938687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.copbio.2016.02.007</pub-id><pub-id pub-id-type="pmcid">PMC4975620</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salmaninejad</surname><given-names>A</given-names></name><name name-style="western"><surname>Valilou</surname><given-names>SF</given-names></name><name name-style="western"><surname>Soltani</surname><given-names>A</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>S</given-names></name><name name-style="western"><surname>Abarghan</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Rosengren</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Tumor-associated macrophages: role in cancer development and therapeutic implications</article-title><source>Cell Oncol (Dordrecht)</source><year>2019</year><volume>42</volume><issue>5</issue><fpage>591</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1007/s13402-019-00453-z</pub-id><pub-id pub-id-type="pmid">31144271</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Salmaninejad A, Valilou SF, Soltani A, Ahmadi S, Abarghan YJ, Rosengren RJ, et al. Tumor-associated macrophages: role in cancer development and therapeutic implications. Cell Oncol (Dordrecht). 2019;42(5):591&#8211;608. 10.1007/s13402-019-00453-z.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13402-019-00453-z</pub-id><pub-id pub-id-type="pmid">31144271</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Horta</surname><given-names>CA</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name></person-group><article-title>Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics</article-title><source>Sem Cancer Biol</source><year>2023</year><volume>88</volume><fpage>46</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2022.12.002</pub-id><pub-id pub-id-type="pmcid">PMC10237282</pub-id><pub-id pub-id-type="pmid">36521737</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Zhang J, Hu Z, Horta CA, Yang J. Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics. Sem Cancer Biol. 2023;88:46&#8211;66. 10.1016/j.semcancer.2022.12.002.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcancer.2022.12.002</pub-id><pub-id pub-id-type="pmcid">PMC10237282</pub-id><pub-id pub-id-type="pmid">36521737</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Han</surname><given-names>J</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>Functional and therapeutic significance of Tumor-Associated macrophages in colorectal cancer</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>781233</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.781233</pub-id><pub-id pub-id-type="pmid">35186730</pub-id><pub-id pub-id-type="pmcid">PMC8847181</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Li Y, Chen Z, Han J, Ma X, Zheng X, Chen J. Functional and therapeutic significance of Tumor-Associated macrophages in colorectal cancer. Front Oncol. 2022;12:781233. 10.3389/fonc.2022.781233.<pub-id pub-id-type="pmid">35186730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2022.781233</pub-id><pub-id pub-id-type="pmcid">PMC8847181</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>Shaping polarization of Tumor-Associated macrophages in cancer immunotherapy</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>888713</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.888713</pub-id><pub-id pub-id-type="pmid">35844605</pub-id><pub-id pub-id-type="pmcid">PMC9280632</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Gao J, Liang Y, Wang L. Shaping polarization of Tumor-Associated macrophages in cancer immunotherapy. Front Immunol. 2022;13:888713. 10.3389/fimmu.2022.888713.<pub-id pub-id-type="pmid">35844605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.888713</pub-id><pub-id pub-id-type="pmcid">PMC9280632</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>A</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>Targeting Treg cells in cancer immunotherapy</article-title><source>Eur J Immunol</source><year>2019</year><volume>49</volume><issue>8</issue><fpage>1140</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1002/eji.201847659</pub-id><pub-id pub-id-type="pmid">31257581</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Tanaka A, Sakaguchi S. Targeting Treg cells in cancer immunotherapy. Eur J Immunol. 2019;49(8):1140&#8211;6. 10.1002/eji.201847659.<pub-id pub-id-type="pmid">31257581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/eji.201847659</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="other">Quail DF, Amulic B, Aziz M, Barnes BJ, Eruslanov E, Fridlender ZG, et al. Neutrophil phenotypes and functions in cancer: A consensus statement. J Exp Med. 2022;219(6). 10.1084/jem.20220011.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20220011</pub-id><pub-id pub-id-type="pmcid">PMC9086501</pub-id><pub-id pub-id-type="pmid">35522219</pub-id></mixed-citation></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grzywa</surname><given-names>TM</given-names></name><name name-style="western"><surname>Sosnowska</surname><given-names>A</given-names></name><name name-style="western"><surname>Matryba</surname><given-names>P</given-names></name><name name-style="western"><surname>Rydzynska</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jasinski</surname><given-names>M</given-names></name><name name-style="western"><surname>Nowis</surname><given-names>D</given-names></name><etal/></person-group><article-title>Myeloid Cell-Derived arginase in cancer immune response</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>938</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.00938</pub-id><pub-id pub-id-type="pmid">32499785</pub-id><pub-id pub-id-type="pmcid">PMC7242730</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Grzywa TM, Sosnowska A, Matryba P, Rydzynska Z, Jasinski M, Nowis D, et al. Myeloid Cell-Derived arginase in cancer immune response. Front Immunol. 2020;11:938. 10.3389/fimmu.2020.00938.<pub-id pub-id-type="pmid">32499785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.00938</pub-id><pub-id pub-id-type="pmcid">PMC7242730</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="other">Folkert IW, Molina Arocho WA, To TKJ, Devalaraja S, Molina IS, Shoush J, et al. An iron-rich subset of macrophages promotes tumor growth through a Bach1-Ednrb axis. J Exp Med. 2024;221(10). 10.1084/jem.20230420.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20230420</pub-id><pub-id pub-id-type="pmcid">PMC11457473</pub-id><pub-id pub-id-type="pmid">39347789</pub-id></mixed-citation></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>EDNRB inhibits the growth and migration of prostate cancer cells by activating the cGMP-PKG pathway</article-title><source>Open Med (Warsaw Poland)</source><year>2024</year><volume>19</volume><issue>1</issue><fpage>20230875</fpage><pub-id pub-id-type="doi">10.1515/med-2023-0875</pub-id><pub-id pub-id-type="pmcid">PMC10775416</pub-id><pub-id pub-id-type="pmid">38205153</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Li X, Liu B, Wang S, Dong Q, Li J. EDNRB inhibits the growth and migration of prostate cancer cells by activating the cGMP-PKG pathway. Open Med (Warsaw Poland). 2024;19(1):20230875. 10.1515/med-2023-0875.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/med-2023-0875</pub-id><pub-id pub-id-type="pmcid">PMC10775416</pub-id><pub-id pub-id-type="pmid">38205153</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thapa</surname><given-names>B</given-names></name><name name-style="western"><surname>Kato</surname><given-names>S</given-names></name><name name-style="western"><surname>Nishizaki</surname><given-names>D</given-names></name><name name-style="western"><surname>Miyashita</surname><given-names>H</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>Nesline</surname><given-names>MK</given-names></name><etal/></person-group><article-title>OX40/OX40 ligand and its role in precision immune oncology</article-title><source>Cancer Metastasis Rev</source><year>2024</year><volume>43</volume><issue>3</issue><fpage>1001</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1007/s10555-024-10184-9</pub-id><pub-id pub-id-type="pmid">38526805</pub-id><pub-id pub-id-type="pmcid">PMC11300540</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Thapa B, Kato S, Nishizaki D, Miyashita H, Lee S, Nesline MK, et al. OX40/OX40 ligand and its role in precision immune oncology. Cancer Metastasis Rev. 2024;43(3):1001&#8211;13. 10.1007/s10555-024-10184-9.<pub-id pub-id-type="pmid">38526805</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10555-024-10184-9</pub-id><pub-id pub-id-type="pmcid">PMC11300540</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madukwe</surname><given-names>JC</given-names></name></person-group><article-title>Overcoming drug resistance in cancer</article-title><source>Cell</source><year>2023</year><volume>186</volume><issue>8</issue><fpage>1515</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2023.03.019</pub-id><pub-id pub-id-type="pmid">37059057</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Madukwe JC. Overcoming drug resistance in cancer. Cell. 2023;186(8):1515&#8211;6. 10.1016/j.cell.2023.03.019.<pub-id pub-id-type="pmid">37059057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2023.03.019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tyner</surname><given-names>JW</given-names></name><name name-style="western"><surname>Haderk</surname><given-names>F</given-names></name><name name-style="western"><surname>Kumaraswamy</surname><given-names>A</given-names></name><name name-style="western"><surname>Baughn</surname><given-names>LB</given-names></name><name name-style="western"><surname>Van Ness</surname><given-names>B</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Understanding drug sensitivity and tackling resistance in cancer</article-title><source>Cancer Res</source><year>2022</year><volume>82</volume><issue>8</issue><fpage>1448</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.Can-21-3695</pub-id><pub-id pub-id-type="pmid">35195258</pub-id><pub-id pub-id-type="pmcid">PMC9018544</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Tyner JW, Haderk F, Kumaraswamy A, Baughn LB, Van Ness B, Liu S, et al. Understanding drug sensitivity and tackling resistance in cancer. Cancer Res. 2022;82(8):1448&#8211;60. 10.1158/0008-5472.Can-21-3695.<pub-id pub-id-type="pmid">35195258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-21-3695</pub-id><pub-id pub-id-type="pmcid">PMC9018544</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>S</given-names></name><name name-style="western"><surname>Fan</surname><given-names>F</given-names></name><name name-style="western"><surname>Powell</surname><given-names>R</given-names></name><name name-style="western"><surname>Park</surname><given-names>YS</given-names></name><name name-style="western"><surname>Stephan</surname><given-names>C</given-names></name><name name-style="western"><surname>Kopetz</surname><given-names>ES</given-names></name><etal/></person-group><article-title>Enhancing efficacy of the MEK inhibitor Trametinib with Paclitaxel in KRAS-mutated colorectal cancer</article-title><source>Therapeutic Adv Med Oncol</source><year>2024</year><volume>16</volume><fpage>17588359241303302</fpage><pub-id pub-id-type="doi">10.1177/17588359241303302</pub-id><pub-id pub-id-type="pmcid">PMC11632859</pub-id><pub-id pub-id-type="pmid">39664300</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Ghosh S, Fan F, Powell R, Park YS, Stephan C, Kopetz ES, et al. Enhancing efficacy of the MEK inhibitor Trametinib with Paclitaxel in KRAS-mutated colorectal cancer. Therapeutic Adv Med Oncol. 2024;16:17588359241303302. 10.1177/17588359241303302.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/17588359241303302</pub-id><pub-id pub-id-type="pmcid">PMC11632859</pub-id><pub-id pub-id-type="pmid">39664300</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="other">Ariyoshi M, Yuge R, Kitadai Y, Shimizu D, Miyamoto R, Yamashita K, et al. WEE1 inhibitor Adavosertib exerts antitumor effects on colorectal cancer, especially in cases with p53 mutations. Cancers. 2024;16(18). 10.3390/cancers16183136.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers16183136</pub-id><pub-id pub-id-type="pmcid">PMC11429655</pub-id><pub-id pub-id-type="pmid">39335109</pub-id></mixed-citation></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>La Salvia</surname><given-names>A</given-names></name><name name-style="western"><surname>Lopez-Gomez</surname><given-names>V</given-names></name><name name-style="western"><surname>Garcia-Carbonero</surname><given-names>R</given-names></name></person-group><article-title>HER2-targeted therapy: an emerging strategy in advanced colorectal cancer</article-title><source>Expert Opin Investig Drugs</source><year>2019</year><volume>28</volume><issue>1</issue><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1080/13543784.2019.1555583</pub-id><pub-id pub-id-type="pmid">30513002</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">La Salvia A, Lopez-Gomez V, Garcia-Carbonero R. HER2-targeted therapy: an emerging strategy in advanced colorectal cancer. Expert Opin Investig Drugs. 2019;28(1):29&#8211;38. 10.1080/13543784.2019.1555583.<pub-id pub-id-type="pmid">30513002</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13543784.2019.1555583</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>